Delamanid is a novel armor recently launched to treat Multidrug Resistance Tuberculosis (MDR-TB). Not much is known about its therapeutic significance. Two powerful anti-TB drugs, isoniazid and rifampicin are ineffective against MDR-TB. Although there are 8 to 9 million new cases of TB annually, TB skin test (TST) data suggest that one-third of the global population are infected. Thus, this article enlightens about delamanid for the management of MDR-TB.
Delamanid, a newer mycobacterial cell wall synthesis inhibitor recently launched to treat MDR-TB. It is the first in a new class of TB drugs called nitroimidazoles. As evident from few clinical studies, it is reported to have fewer side effects. How does MDR-TB originate?-Probable foundations Improper Management Patient does not complete a full course of TB treatment The wrong dose or length of time Inefficient drugs Frequent…
